Dupilumab Efficacy in Asthma Patients With FEV1 60-80% Predicted on Medium-Dose ICS: liberty asthma quest Study

被引：1
|
作者：
Papi, Alberto [1 ]
Pavord, Ian D. [2 ]
Fitzgerald, J. Mark [3 ]
Corren, Jonathan [4 ]
Bardin, Philip [5 ,6 ,7 ,8 ]
Park, Hae Sim [9 ]
Rice, Megan S. [10 ]
Deniz, Yamo [11 ]
Rowe, Paul [12 ]
Staudinger, Heribert [12 ]
Amin, Nikhil [11 ]
Ruddy, Marcella [11 ]
Graham, Neil M. H. [11 ]
Teper, Ariel [12 ]
机构：
[1] Univ Hosp Santa Anna, Ferrara, Italy
[2] NIHR Oxford Biomed Res Ctr, Oxford, England
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Monash Univ, Melbourne, Vic, Australia
[6] Monash Med Ctr, Melbourne, Vic, Australia
[7] Monash Univ, Clayton, Vic, Australia
[8] Monash Med Ctr, Clayton, Vic, Australia
[9] Ajou Univ, Suwon, South Korea
[10] Sanofi, Cambridge, MA USA
[11] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[12] Sanofi, Bridgewater, MA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
Asthma; -; management;
D O I：
10.1183/13993003.congress-2019.PA538
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA538
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Dupilumab Reduced Severe Exacerbation Rates and Improved Pre-bronchodilator Fev1 in Patients With Moderate-to-Severe Asthma Regardless of Exacerbation History of ≥1, ≥2, or ≥3 Prior Exacerbations: Liberty Asthma Traverse
    Maspero, J. F.
    Corren, J.
    Katelaris, C.
    Castro, M.
    Humbert, M. J.
    Halpin, D. M.
    Altincatal, A.
    Pandit-Abid, N.
    Soler, X.
    Radwan, A.
    Jacob-Nara, J. A.
    Deniz, Y. M.
    Rowe, P. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [42] EFFICACY OF DUPILUMAB IN CHILDREN WITH UNCONTROLLED TYPE 2 ASTHMA RECEIVING HIGH/MEDIUM DOSES OF INHALED CORTICOSTEROIDS AT BASELINE: THE LIBERTY ASTHMA VOYAGE STUDY
    Maspero, Jorge F.
    Antila, Martti
    Jain, Neal
    Deschildre, Antoine
    Bacharier, Leonard B.
    Altincatal, Arman
    Laws, Elizabeth
    Akinlade, Bolanle
    Siddiqui, Shahid
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Lederer, David J.
    Hardin, Megan
    CHEST, 2022, 162 (04) : 1945A - 1947A
  • [43] A LONGITUDINAL-STUDY OF BASE-LINE FEV1 AND BRONCHIAL RESPONSIVENESS IN PATIENTS WITH ASTHMA
    JOSEPHS, LK
    GREGG, I
    MULLEE, MA
    CAMPBELL, MJ
    HOLGATE, ST
    EUROPEAN RESPIRATORY JOURNAL, 1992, 5 (01) : 32 - 39
  • [44] Impact of age of asthma onset on the long-term efficacy of Dupilumab in patients with type 2 inflammation: Liberty asthma traverse study
    Busse, W. W.
    Kraft, M.
    Domingo, C.
    De Mir, I.
    Maselli, D.
    Soler, X.
    Xia, C.
    Pandit-Abid, N.
    Jacob-Nara, J. A.
    Sacks, H.
    Rowe, P. J.
    Deniz, Y.
    ALLERGY, 2023, 78 : 54 - 55
  • [45] DUPILUMAB DEMONSTRATES RAPID AND SUSTAINED IMPROVEMENTS IN DAILY ASTHMA-RELATED SYMPTOMS IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA: DATA FROM THE LIBERTY ASTHMA QUEST STUDY
    Douglass, Jo
    Langton, David
    Corren, Jonathan
    Castro, Mario
    Guillonneau, Sophie
    Chao, Jingdong
    Amin, Nikhil
    Graham, Neil M. H.
    Teper, Ariel
    Khan, Asif
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 22 - 23
  • [46] Effect Of Dupilumab On Fev1 And Severe Exacerbations In Patients With Uncontrolled Persistent Asthma: A Subgroup Analysis Defined According To Early-Onset And Late-Onset Asthma
    Weinstein, S. F.
    Ford, L. B.
    Zhang, B.
    Pirozzi, G.
    Staudinger, H.
    Evans, R. R.
    Graham, N. M. H.
    Louis-Tisserand, M.
    Teper, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [47] Identification of Patients with Uncontrolled, Moderate-to-Severe Asthma with High Sleep Disturbance and Efficacy of Dupilumab in This Subgroup: Post-Hoc Analysis from LIBERTY ASTHMA QUEST
    Maspero, J. F.
    Shafazand, S.
    Cole, J.
    Pavord, I. D.
    Busse, W. W.
    Msihid, J.
    Gall, R.
    Soler, X.
    Siddiqui, S.
    Khan, A.
    Gomez, L. De Prado
    Jacob-Nara, J. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [48] Dupilumab Provides Rapid and Sustained Exacerbation Protection in Patients with Uncontrolled, Moderate-to-Severe Type 2 Inflammatory Asthma Enrolled in the LIBERTY ASTHMA QUEST Study
    Corren, J.
    Rogers, L.
    Papi, A.
    Chen, Z.
    Pandit-Abid, N.
    Rowe, P.
    Deniz, Y.
    Ortiz, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [49] DUPILUMAB REDUCES SEVERE EXACERBATION RATE AND IMPROVES LUNG FUNCTION IN ADOLESCENT PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA: FROM THE LIBERTY ASTHMA QUEST STUDY
    Maspero, Jorge
    Fitzgerald, Mark
    Pavord, Ian
    Wenzel, Sally
    Zhang, Bingzhi
    Maroni, Jaman
    Rowe, Paul
    Amin, Nikhil
    Pirozzi, Gianluca
    Ruddy, Marcella
    Akinlade, Bolanle
    Graham, Neil
    Teper, Ariel
    CHEST, 2018, 154 (04) : 25A - 27A
  • [50] Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study
    Tohda, Yuji
    Nakamura, Yoichi
    Fujisawa, Takao
    Ebisawa, Motohiro
    Msihid, Jerome
    Djandji, Michel
    Ortiz, Benjamin
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Ishida, Masato
    Arima, Kazuhiko
    ALLERGOLOGY INTERNATIONAL, 2023, 72 (01) : 89 - 99
12345